Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-007963Source: DataRank Database

Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer is a research paper published in Journal for ImmunoTherapy of Cancer (2024). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)Impact (FWCI 3.64)OA: goldTopics (100)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Lauren E Farley,Rayna M Harris ORCID,Sean J. Judge ORCID,Marshall Lammers ORCID,Khurshid Iranpur

Live enrichment

PubMed:38631708 OpenAlex:https://openalex.org/W4394893387

V Foundation

Grant: N/A

University of California Davis Flow Cytometry Shared Resource Laboratory

Grant: S10 RR 026825

the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health

Grant: UL1 TR001860

UC Davis Comprehensive Cancer Center

Grant: P30 CA093373

National Institute of Health/National Cancer Institute

Grant: F30CA275317

National Institute of Health/National Cancer Institute

Grant: R03CA252793

National Institute of Health/National Cancer Institute

Grant: R03CA270854

National Institute of Health/National Cancer Institute

Grant: U01 CA224166-01

National Institutes of Health

Grant: 3P30CA093373-07S2

Cancer Center Support Grant - P30

National Institutes of Health

Grant: 5UL1TR001860-10

UC Davis Clinical and Translational Science Center

National Institutes of Health

Grant: 1U01CA224166-01

Enhancing natural killer immunotherapy with first-in-dog trials of inhaled recombinant IL-15 and super-agonist IL-15 in naturally occurring canine cancers

National Institutes of Health

Grant: 5F30CA275317-02

Combining Radiation, Allogeneic Natural Killer Immunotherapy, and PD-L1 blockade in Dogs with Naturally-Occurring Melanoma

National Institutes of Health

Grant: 5R03CA270854-02

Targeting Lung Tissue Resident NK Cells with Inhaled IL-15 and TIGIT Blockade in Osteosarcoma

National Institutes of Health

Grant: 5R03CA252793-02

Gene Expression Analysis of Dog Natural Killer Cells as Immunotherapy Target

National Institutes of Health

Grant: 1S10OD010786-01

Acquisition of Covaris E220 and Sciclone G3 systems for high throughput sequencin

NCI NIH HHS

Grant: T32 CA251007

NCI NIH HHS

Grant: P30 CA008748

NIH HHS

Grant: S10 OD010786

NCI NIH HHS

Grant: U01 CA224166

FWCI

3.64

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by-nc

journalhttps://jitc.bmj.com/content/jitc/12/4/e007963.full.pdf

publisherhttps://jitc.bmj.com/content/jitc/12/4/e007963.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1136/jitc-2023-007963

journalhttps://doi.org/10.1136/jitc-2023-007963

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38631708

Fields of Study

Immune Cell Function and InteractionXenotransplantation and immune responseAnimal health and immunology0301 basic medicine0403 veterinary science04 agricultural and veterinary sciences03 medical and health sciencesDogsAnimalsHumansImmunotherapy, AdoptiveLeukocytes, MononuclearCytotoxicity, ImmunologicKiller Cells, NaturalOsteosarcomaBone NeoplasmsCytokines

MeSH Terms

AnimalsBone NeoplasmsCytotoxicity, ImmunologicDogsHumansKiller Cells, NaturalLeukocytes, MononuclearOsteosarcomaCytokinesImmunotherapy, Adoptive

Keywords

Peripheral blood mononuclear cellImmunotherapyCancer immunotherapyImmune systemImmunologyCancer researchCytotoxic T cellMedicineInterleukin 21BiologyT cellIn vitroCytotoxicity, ImmunologicCytotoxicityAdoptiveImmunotherapy, AdoptiveAdoptive (mesh)killer cellsClinical Research (rcdc)computational biologyImmunologicLeukocytesAnimals (mesh)Immunization (rcdc)32 Biomedical and Clinical Sciences (for-2020)RC254-282CancerOsteosarcoma (mesh)Cancer (rcdc)Humans (mesh)Osteosarcomaclinical trials as topicNeoplasms. Tumors. Oncology. Including cancer and carcinogens600Killer Cells, NaturalVaccine Related (rcdc)NaturalCytokinesBiotechnologyBone Neoplasms (mesh)Immunologic (mesh)Dogs (mesh)Oncology and CarcinogenesisClinical Trials and Supportive ActivitiesMononuclearClinical Trials and Supportive Activities (rcdc)610Bone NeoplasmsBiotechnology (rcdc)Vaccine RelatedRare Diseases (rcdc)Rare DiseasesDogsClinical ResearchGenetics3211 Oncology and carcinogenesis (for-2020)AnimalsHumans3204 Immunology (for-2020)Natural (mesh)Biomedical and Clinical Sciences5.2 Cellular and gene therapiesImmune Cell Therapies and Immune Cell EngineeringGenetics (rcdc)Immunotherapy (rcdc)adoptive cell therapy5.2 Cellular and gene therapies (hrcs-rac)Cancer (hrcs-hc)Mononuclear (mesh)Cytokines (mesh)Leukocytes, MononuclearImmunizationadoptive cell therapy (ACT)

Sustainable Development Goals

SDG 3: 3. Good health